Request Demo
Last update 16 May 2025
Dexrazoxane Hydrochloride
Last update 16 May 2025
Overview
Basic Info
Drug Type Small molecule drug |
Synonyms dexrazoxane, Topotect, Totect + [13] |
Target |
Action inhibitors |
Mechanism Top II inhibitors(Topoisomerase II inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date United States (26 May 1995), |
RegulationAccelerated Approval (United States), Orphan Drug (United States), Orphan Drug (Australia) |
Login to view timeline
Structure/Sequence
Molecular FormulaC11H17ClN4O4 |
InChIKeyBIFMNMPSIYHKDN-FJXQXJEOSA-N |
CAS Registry149003-01-0 |
Related
54
Clinical Trials associated with Dexrazoxane HydrochlorideChiCTR2500101472
Early Application of Edaravone Dexrazoxane In The Treatment of Acute Non-Large Vessel Occlusive Ischemic Stroke
NCT06647953
Prospective Treatment of Types I, II and III Pleuropulmonary Blastoma (PPB)
NCT06220032
ANTICIPATE: Prevention of ANThracycline-Induced Cardiac Dysfunction by Dexrazoxane In PATients With diffusE Large B-cell Lymphoma: a Phase III National Multicenter Prospective Randomized Open-label Trial
100 Clinical Results associated with Dexrazoxane Hydrochloride
Login to view more data
100 Translational Medicine associated with Dexrazoxane Hydrochloride
Login to view more data
100 Patents (Medical) associated with Dexrazoxane Hydrochloride
Login to view more data
1,212
Literatures (Medical) associated with Dexrazoxane Hydrochloride01 Dec 2025Natural Products and Bioprospecting
Design, synthesis and biological evaluation of buthutin derivatives as cardioprotective agents
Article
Author: Liu, Yu-Ming ; Wang, Li-Ning ; Gou, Xiang-Bo ; Yang, Shu-Han ; Hua, Xin-Hao ; Wang, Fa-Qi ; Xu, Yun-Sheng ; Liu, Yuan ; Shao, Chen-Yue
Abstract:
Natural products are the important sources in cardiovascular drug development. In this study, twenty-nine buthutin derivatives were designed, synthesized, and evaluated for their NHE-1 inhibition and protective effects on cardiomyocyte injury. The structure of the newly synthesized compounds had been confirmed by 1H-NMR, 13C-NMR, and HR-ESI-MS spectra. Among all target compounds at 1 μM, compounds 9d, 9f, 9k, 9m, and 9n, with a protection ratio exceeding 30%, exerted stronger protective effects on H9c2 cardiomyocyte than positive control dexrazoxane and buthutin A. Meanwhile, compounds 9k, 9m, and 9o showed the significant NHE-1 inhibitory activities on H9c2 cardiomyocyte, all with a dpHi/min value less than 0.23. What is more, compounds 9k, 9m, 9o and buthutin A all exhibited the specificity on NHE-1 inhibition. Molecular modelling studies suggested the ability of compounds 9m and 9o to establish interactions with three hydrogen bonds to Asp267 and Glu346 of NHE-1, but also the ability with much lower CDOCKER energies than positive control cariporide and buthutin A. The structure–activity relationship (SAR) studies suggested that the presences of amide group, four-carbon linker, and para hydroxyl benzene ring were advantageous pharmacophores for above two pharmacological actions. This research would open new avenues for developing amide-guanidine-based cardioprotective agents.Graphical Abstract
01 Jun 2025PHYTOMEDICINE
Erianin alleviates doxorubicin-induced cardiotoxicity by activating the Keap1-Nrf2 signaling pathway
Article
Author: Kang, Shiyao ; Li, Huimin ; Li, Ming ; Zhao, Yuan ; Sheng, Miaomiao ; Dan, Juhua ; Pang, Jianyu
BACKGROUND:
Doxorubicin (DOX) has significant toxic side effects on cardiomyocytes, and existing preventive drug dexrazoxane has serious side effects. Therefore, in-depth research on drugs that can enhance the antitumor effect of DOX and simultaneously reduce its cardiotoxicity is of crucial significance. Our study explored the regulatory role of Erianin in DOX-induced cardiotoxicity and the specific molecular mechanism.
METHODS:
In this study, we constructed a myocardial injury model in mice with DOX. The toxic side effects of DOX on the organism were determined by recording the weight changes of the mice and calculating the spleen index and heart-tibia ratio of the mice. The degree of myocardial injury in mice was evaluated by methods such as echocardiography and Sirius red staining. Further in vivo experiments were conducted to verify whether the silencing of Nrf2 could block the protective effect of Erianin on myocardial cells.
RESULTS:
We found Erianin significantly alleviated DOX-induced cardiomyocyte injury (p < 0.0001), increased heart tissue pumping efficiency and contractility (p < 0.001), and reduced myocardial cell fibrosis. Mechanism study showed that Erianin can bind to Keap1, promote its ubiquitination and autophagic degradation, increase the acetylation of lysine 599 site in Nrf2 protein, and activate the antioxidant stress response.
CONCLUSIONS:
Taken together, our study had for the first time elucidated the molecular mechanism by which Erianin alleviated DOX-induced myocardial injury by activating the Keap1-Nrf2 signaling pathway. It provides a theoretical basis for the development of Erianin as a potential protective drug for DOX-induced cardiotoxicity. It has very important clinical application and translational value.
01 Jun 2025ACTA TROPICA
Dexrazoxane as a viable microsporidia control agent in Anopheles gambiae
Article
Author: Silva, Luis M ; Zeferino, Tiago G
Microsporidia have long been proposed as biological agents for controlling disease vectors and the parasites they transmit. However, their study in vector biology has been constrained due to challenges in manipulating microsporidia within hosts. In this study, we investigated the effect of Dexrazoxane, a candidate drug against microsporidiosis, on the establishment and development of Vavraia culicis infection in its natural host, the mosquito Anopheles gambiae, the main malaria vector. Our findings show that Dexrazoxane significantly reduces spore load, particularly in mosquitoes reared individually, without affecting the overall infection success of the parasite. This result aligns with studies in Caenorhabditis elegans, where Dexrazoxane inhibited new spore production without hindering initial spore integration into the host gut cells. Dexrazoxane's DNA topoisomerase II inhibitor mechanism likely explains its impact on mosquito development, as larvae exposed to the drug failed to emerge as adults. These findings highlight Dexrazoxane's potential as a viable tool for controlling microsporidia in adult mosquitoes and hope to enhance the study of mosquito-microsporidia interactions. Further research is required to explore its broader application in vector-borne disease control, including malaria.
4
News (Medical) associated with Dexrazoxane Hydrochloride11 Aug 2023
AcquisitionLicense out/in
10 Aug 2023
AcquisitionRadiation Therapy
13 Feb 2019
AcquisitionLicense out/in
100 Deals associated with Dexrazoxane Hydrochloride
Login to view more data
External Link
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| D07807 | Dexrazoxane Hydrochloride |
R&D Status
Approved
10 top approved records. to view more data
Login
| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Extravasation of Diagnostic and Therapeutic Materials | European Union | 27 Jul 2006 | |
| Extravasation of Diagnostic and Therapeutic Materials | Iceland | 27 Jul 2006 | |
| Extravasation of Diagnostic and Therapeutic Materials | Liechtenstein | 27 Jul 2006 | |
| Extravasation of Diagnostic and Therapeutic Materials | Norway | 27 Jul 2006 | |
| Cytoprotective Agent | China | 29 May 2006 | |
| Cardiomyopathies | United States | 26 May 1995 | |
| Metastatic breast cancer | United States | 26 May 1995 |
Developing
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hemorrhage | Phase 3 | Denmark | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | Germany | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | Italy | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | Netherlands | 01 Apr 2002 | |
| Hemorrhage | Phase 3 | Poland | 01 Apr 2002 | |
| Bronchitis | Phase 3 | Denmark | 01 Jun 2001 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Not Applicable | - | iahpborcmp(mynpxvvljd) = enoxtitrby foivryotxn (eutsaoaxru ) View more | - | 07 Dec 2024 | |||
Non-initiators of Dexrazoxane | iahpborcmp(mynpxvvljd) = jsiabjeltz foivryotxn (eutsaoaxru ) View more | ||||||
Not Applicable | 142 | Anthracycline + Dexrazoxane | qbvbrklzkj(xjganvkafn) = ydsdfwninz lcpnlzfhms (gohjcerhtn ) | Positive | 31 May 2023 | ||
Anthracycline only | qbvbrklzkj(xjganvkafn) = ifgizildqh lcpnlzfhms (gohjcerhtn ) View more | ||||||
Not Applicable | 263 | grnxobdaog(vuveualomr) = huzsmcjppb olzyhopwon (vyivdwyqrt ) View more | - | 03 Dec 2022 | |||
grnxobdaog(vuveualomr) = skgwiihxwq olzyhopwon (vyivdwyqrt ) View more | |||||||
Not Applicable | - | 1,308 | Doxorubicin with dexrazoxane | lkzsmumrrc(ahzicxidsd): HR = 1.07 (95% CI, 0.78 - 1.47) View more | - | 15 Feb 2022 | |
Doxorubicin without dexrazoxane | |||||||
Not Applicable | 2,375 | ywxugsggxf(blqfrhgqoe): OR = 1.15 (95% CI, 0.57 - 2.31), P-Value = 0.7 View more | - | 29 Jun 2021 | |||
No drug or placebo | |||||||
Not Applicable | 173 | ratycrrwxo(nutxszujsk) = bavfkttpkt uwungtohig (lsjwhncbkd, 6.0 - 18.0) View more | Positive | 25 May 2020 | |||
ratycrrwxo(nutxszujsk) = rodfmopafq uwungtohig (lsjwhncbkd, 6.0 - 28.2) View more | |||||||
Phase 2 | 46 | (Arm A: VACdxr With ImmTher) | saougkdieh(ewkjmldjlc) = idpdcecrpj qsfgyopdww (zprihqzpiz, fnbboezrvt - pmrqphurqp) View more | - | 29 Jan 2020 | ||
(Arm B: VACdxr) | saougkdieh(ewkjmldjlc) = hpvijgziiu qsfgyopdww (zprihqzpiz, gxmzxjccha - euanaofanq) View more | ||||||
Phase 1 | 1 | gjgdggcowm = edywqcsnad oycmjhfuku (zcaeajgfpu, btlqkosyux - nyjjqnhlgv) View more | - | 19 Feb 2019 | |||
Not Applicable | Breast Cancer Adjuvant | 1,545 | fdiotkfznv(jjsqjlviqq): RR = 0.262 (95% CI, 0.169 - 0.407) View more | Positive | 01 Jun 2018 | ||
Anthracycline-based chemotherapy | |||||||
Not Applicable | 1,014 | gxgjvpxivp(ldxfpmvpeh) = vcrgaswhtm ljmmryidlc (bujzlyhinx ) View more | Positive | 01 Jun 2018 | |||
gxgjvpxivp(ldxfpmvpeh) = pucozfknpv ljmmryidlc (bujzlyhinx ) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free